News | June 15, 2012

Vascular Solutions Acquires Accumed Radial Access Wrist Splint Product

$1.5 million purchase for wrist splint product assets with annual sales approaching $500,000?

June 15, 2012 — Vascular Solutions Inc. today announced that it has acquired the radial artery access wrist positioning splint product assets of privately-held Accumed Systems Inc. Since 1999, Accumed has sold the wrist positioning splint product exclusively in the United States via a company website, with current annualized sales approaching $500,000.

Radial artery access for coronary angiography and interventional procedures is now undergoing significant expansion in the United States, due mainly to reduced patient recovery times and improved patient comfort. The Accumed device is designed to simplify arterial access during radial procedures, for both the physician and patient, by holding the wrist and forearm in an appropriate and comfortable position and by eliminating unwanted hand and arm movement during and after the procedure.

The purchase price was $1.5 million, which was paid with cash on hand. Vascular Solutions expects the transaction to have an immediate
accretive impact on net income, although the addition of the wrist splint business will not have a material impact on 2012 earnings per share. Beginning in 2013, Vascular Solutions expects the product to be modestly accretive on an earnings per share basis. Under the terms of the agreement, Accumed will manufacture the product for sale by Vascular Solutions through the end of 2014, after which time Vascular Solutions will assume responsibility for manufacturing the device.

For more information:


Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init